DTIL - Precision BioSciences, Inc.
| Previous Close | 10.05 |
| Open | 10.08 |
| Bid | 9.67 x 1800 |
| Ask | 9.65 x 900 |
| Day's Range | 9.61 - 10.10 |
| 52 Week Range | 7.80 - 19.00 |
| Volume | 101,698 |
| Avg. Volume | 161,209 |
| Market Cap | 504.378M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.12 |
| Earnings Date | Aug 14, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.17 |
- American City Business Journals
Durham drugmaker pushes forward with its latest clinical cancer treatment
Riding on the momentum of its recent initial public offering, a Triangle gene therapy company is launching its second potential cancer treatment into clinical trials.
- GlobeNewswire
Precision BioSciences Announces FDA Clearance of the IND for PBCAR20A, a CD20 Targeting Genome Edited Allogeneic CAR T Therapy
Precision BioSciences, Inc. (DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for PBCAR20A, the Company’s second off-the-shelf chimeric antigen receptor (CAR) T cell therapy program. Wholly owned by Precision, PBCAR20A is an allogeneic anti-CD20 CAR T therapy candidate in development for the treatment of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL).
- GlobeNewswire
Precision BioSciences to Present at Upcoming Scientific Conferences
DURHAM, N.C., Sept. 04, 2019 -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its.
- GlobeNewswire
Precision BioSciences to Present at Upcoming Investor Conferences
DURHAM, N.C., Aug. 28, 2019 -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its.
- GlobeNewswire
Precision BioSciences Reports Second Quarter 2019 Financial Results and Highlights Ongoing Operational Progress
DURHAM, N.C., Aug. 14, 2019 -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its.
- Barrons.com
Big IPOs Like Beyond Meat Have Had a Good Year. WeWork Wants In.
Most of 2019’s biggest initial public offerings, including Beyond Meat, have outperformed the S&P 500 relative to their offer prices. That’s likely one reason WeWork parent We Co. has filed for an IPO.
- American City Business Journals
Looking ahead, Precision bets $26 million on Durham
Coming out of its debut on the public market, a biotechnology company is doubling-down on its investments throughout Durham and the Triangle.
- American City Business Journals
Durham firm, flush with IPO dollars, opens manufacturing center in RTP
Putting some of its IPO money to use, newly public Precision Biosciences has opened a manufacturing center to prepare it for both commercial manufacturing and clinical development.
- GlobeNewswire
Precision BioSciences Opens First In-House cGMP Manufacturing Facility Dedicated to Genome-Edited Allogeneic CAR T Cell Therapy in the United States
Precision BioSciences, Inc. (DTIL), a genome editing company dedicated to improving life through the application of its proprietary ARCUS® genome editing platform, announced today the opening of its Manufacturing Center for Advanced Therapeutics (MCAT), the first in-house current Good Manufacturing Process (cGMP) compliant manufacturing facility in the United States dedicated to genome-edited, off-the-shelf chimeric antigen receptor (CAR) T cell therapy products. This is part of a larger investment by the company in its cancer immunotherapy platform and facilities expansions in North Carolina in 2019. This new facility expands Precision BioSciences’ footprint, adding to a thriving North Carolina life sciences industry and providing opportunities for new high-skill jobs with a focus on manufacturing.
- GlobeNewswire
Elo Life Systems’ Mario G. Pennisi Awarded BIO Leadership and Legacy Award in Industrial Biotechnology and Agriculture at BIO World Congress
Elo Life Systems Inc. (“Elo”), a wholly owned subsidiary of Precision BioSciences, Inc. (DTIL) announced today that Mario G. Pennisi, Resident Director of Elo’s Australian subsidiary located in Brisbane, Australia, received the BIO Leadership and Legacy Award in Industrial Biotech and Agriculture. Mr. Pennisi was honored with this award during the BIO World Congress, which is taking place from July 8-11, 2019 in Iowa.
- Simply Wall St.
How Much Of Precision BioSciences, Inc. (NASDAQ:DTIL) Do Insiders Own?
If you want to know who really controls Precision BioSciences, Inc. (NASDAQ:DTIL), then you'll have to look at the...
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Precision BioSciences, Inc. (DTIL)
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]
- GlobeNewswire
Precision BioSciences Appoints Dario Scimeca as General Counsel
DURHAM, N.C., June 12, 2019 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary.
- Motley Fool
Is the Newest Gene Editing Stock a Buy?
Precision BioSciences raised over $170 million in net proceeds from its initial public offering in late March.
- American City Business Journals
Just coming out of IPO, Precision strikes $50 million credit deal with bank
Just months following the company's $130 million initial public offering, Precision Biosciences has announced a $50 million credit agreement with a West Coast bank.
- GlobeNewswire
Precision BioSciences Appoints Christopher R. Heery, M.D., as Chief Medical Officer
“We are thrilled to welcome Chris Heery as our Chief Medical Officer. Chris has exceptional experience in the rapidly evolving field of cell therapies and has led many first-in-human clinical trials during his time at the National Cancer Institute (NCI).
- GlobeNewswire
Precision BioSciences Announces Presentations at the 14th Annual Terrapinn World Advanced Therapies & Regenerative Medicine Congress & Expo 2019
DURHAM, N.C., May 09, 2019 -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary.
- Associated Press
Precision BioSciences: 1Q Earnings Snapshot
The Durham, North Carolina-based company said it had a loss of $1.99 per share. Losses, adjusted for non-recurring costs, were $1.19 per share. The genome editing company posted revenue of $5.5 million ...
- GlobeNewswire
Precision BioSciences Reports First Quarter 2019 Financial Results
DURHAM, N.C., April 29, 2019 -- Precision BioSciences, a genome editing company dedicated to improving life (Nasdaq: DTIL) (“Precision”) through the application of its.
- GlobeNewswire
Precision BioSciences Announces Presentations at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy
DURHAM, N.C., April 24, 2019 -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS®.
- GlobeNewswire
Precision BioSciences Announces Dosing of First Patient in Off-The-Shelf CAR T Cell Therapy Phase 1/2a Clinical Trial
Precision BioSciences (DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS® genome editing platform, announced today it has dosed the first patient in the Phase 1/2a clinical trial of PBCAR0191, its first gene-edited allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate. Precision is developing PBCAR0191 in collaboration with Servier, an international pharmaceutical company.
- GlobeNewswire
Precision BioSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
DURHAM, N.C., April 01, 2019 -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS.
- American City Business Journals
By the numbers: Precision Biosciences' largest shareholders
It’s been a good week for some Precision Biosciences executives and investors, whose shares of the Triangle’s newest public company are now worth millions.
